| 2026 |
| 03/06 | 4,220 | 4,310 | 4,205 | 4,285 | +0.47% | 143,900 | 1891億3874万 | +1.35% |
| 03/05 | 4,315 | 4,325 | 4,260 | 4,265 | +0.47% | 163,800 | 1882億5594万 | +1.11% |
| 03/04 | 4,240 | 4,250 | 4,175 | 4,245 | -0.93% | 230,600 | 1873億7315万 | +0.76% |
| 03/03 | 4,350 | 4,370 | 4,285 | 4,285 | -2.28% | 173,800 | 1891億3874万 | +1.78% |
| 03/02 | 4,420 | 4,420 | 4,350 | 4,385 | -1.13% | 171,100 | 1935億5271万 | +4.21% |
| 02/27 | 4,315 | 4,445 | 4,305 | 4,435 | +2.42% | 205,100 | 1957億5970万 | +5.6% |
| 02/26 | 4,360 | 4,365 | 4,310 | 4,330 | -1.03% | 146,200 | 1911億2503万 | +3.39% |
| 02/25 | 4,330 | 4,390 | 4,305 | 4,375 | +1.63% | 164,100 | 1931億1131万 | +4.64% |
| 02/24 | 4,270 | 4,330 | 4,260 | 4,305 | +0.82% | 167,400 | 1900億2153万 | +3.19% |
| 02/20 | 4,240 | 4,285 | 4,240 | 4,270 | -0.47% | 74,200 | 1884億7664万 | +2.55% |
| 02/19 | 4,225 | 4,290 | 4,195 | 4,290 | +0.94% | 150,900 | 1893億5944万 | +3.22% |
| 02/18 | 4,245 | 4,260 | 4,225 | 4,250 | +0.95% | 77,000 | 1875億9385万 | +2.41% |
| 02/17 | 4,230 | 4,235 | 4,195 | 4,210 | -0.47% | 86,300 | 1858億2826万 | +1.62% |
| 02/17 | （空売り報告）Citigroup Global Markets Limited 197,743株（0.44%）-0.13%義務消失 |
| 02/16 | 4,235 | 4,270 | 4,190 | 4,230 | +0.12% | 141,100 | 1867億1105万 | +2.22% |
| 02/13 | 4,230 | 4,235 | 4,180 | 4,225 | +0.12% | 102,700 | 1864億9035万 | +2.25% |
| 02/12 | 4,215 | 4,255 | 4,205 | 4,220 | +0.12% | 178,500 | 1862億6966万 | +2.28% |
| 02/12 | （空売り報告）Citigroup Global Markets Limited 252,643株（0.57%）-0.11% |
| 02/10 | 4,170 | 4,235 | 4,170 | 4,215 | +0.72% | 141,800 | 1860億4896万 | +2.41% |
| 02/09 | 4,210 | 4,225 | 4,160 | 4,185 | +1.45% | 270,800 | 1847億2477万 | +1.87% |
| 02/09 | （空売り報告）Citigroup Global Markets Limited 301,943株（0.68%）-0.02% |
| 02/06 | （IR情報）15:30 2026年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/06 | 4,110 | 4,140 | 4,095 | 4,125 | -0.12% | 122,800 | 1820億7638万 | +0.59% |
| 02/06 | （空売り報告）Citigroup Global Markets Limited 312,743株（0.7%）+0.03% |
| 02/05 | 4,150 | 4,165 | 4,130 | 4,130 | +0.24% | 151,400 | 1822億9708万 | +0.81% |
| 02/05 | （空売り報告）Citigroup Global Markets Limited 299,443株（0.67%）+0.11% |
| 02/04 | 4,120 | 4,150 | 4,110 | 4,120 | -0.24% | 106,800 | 1818億5568万 | +0.59% |
| 02/04 | （空売り報告）Citigroup Global Markets Limited 249,443株（0.56%）新規 |
| 02/03 | 4,105 | 4,145 | 4,080 | 4,130 | +1.23% | 125,900 | 1822億9708万 | +0.81% |
| 02/02 | 4,125 | 4,130 | 4,080 | 4,080 | +0.37% | 135,400 | 1800億9009万 | -0.37% |
| 01/30 | 4,080 | 4,085 | 4,040 | 4,065 | +0.49% | 105,400 | 1794億2800万 | -0.73% |
| 01/29 | 4,015 | 4,065 | 3,990 | 4,045 | +0.12% | 221,700 | 1785億4520万 | -1.2% |
| 01/28 | 4,100 | 4,105 | 4,040 | 4,040 | -2.42% | 181,500 | 1783億2450万 | -1.29% |
| 01/27 | 4,120 | 4,170 | 4,095 | 4,140 | -0.72% | 154,100 | 1827億3848万 | +1.1% |
| 01/26 | 4,195 | 4,200 | 4,145 | 4,170 | -1.3% | 128,000 | 1840億6267万 | +1.96% |
| 01/23 | 4,200 | 4,240 | 4,180 | 4,225 | +0.6% | 114,200 | 1864億9035万 | +3.45% |
| 01/22 | 4,140 | 4,205 | 4,140 | 4,200 | +1.57% | 145,100 | 1853億8686万 | +3.04% |
| 01/21 | 4,135 | 4,160 | 4,105 | 4,135 | -0.36% | 114,100 | 1825億1778万 | +1.72% |
| 01/20 | 4,120 | 4,165 | 4,100 | 4,150 | 0% | 109,700 | 1831億7987万 | +2.32% |
| 01/19 | （IR情報）9:30 原発性腋窩多汗症治療剤「ECCLOCK」の韓国における発売について |
| 01/19 | 4,090 | 4,155 | 4,090 | 4,150 | +1.47% | 150,000 | 1831億7987万 | +2.49% |
| 01/16 | 4,080 | 4,120 | 4,055 | 4,090 | 0% | 123,600 | 1805億3149万 | +1.29% |
| 01/15 | 4,135 | 4,140 | 4,085 | 4,090 | -0.73% | 110,400 | 1805億3149万 | +1.54% |
| 01/14 | 4,080 | 4,135 | 4,080 | 4,120 | +0.98% | 133,200 | 1818億5568万 | +2.62% |
| 01/13 | 4,130 | 4,130 | 4,070 | 4,080 | -0.49% | 152,700 | 1800億9009万 | +1.95% |
| 01/09 | 4,070 | 4,115 | 4,070 | 4,100 | +0.61% | 106,400 | 1809億7289万 | +2.78% |
| 01/08 | 4,080 | 4,120 | 4,050 | 4,075 | 0% | 169,600 | 1798億6939万 | +2.44% |
| 01/07 | 4,010 | 4,080 | 3,990 | 4,075 | +2.64% | 221,700 | 1798億6939万 | +2.7% |
| 01/07 | （IR情報）8:30 TYK2阻害剤「ESK-001」の 第III相臨床試験「ONWARD1」及び「ONWARD2」結果速報に関する アルミス社の発表について |
| 01/06 | 4,000 | 4,015 | 3,965 | 3,970 | -1.12% | 177,900 | 1752億3472万 | +0.25% |
| 01/05 | 3,995 | 4,030 | 3,960 | 4,015 | 0% | 202,600 | 1772億2101万 | +1.54% |
| 2025 |
| 12/30 | 4,005 | 4,060 | 4,000 | 4,015 | +0.25% | 199,200 | 1772億2101万 | +1.72% |
| 12/29 | 4,060 | 4,090 | 3,975 | 4,005 | -2.91% | 379,100 | 1767億7961万 | +1.7% |
| 12/26 | 4,115 | 4,135 | 4,105 | 4,125 | 0% | 73,100 | 1820億7638万 | +4.99% |
| 12/25 | 4,085 | 4,135 | 4,085 | 4,125 | +0.98% | 71,600 | 1820億7638万 | +5.44% |
| 12/24 | 4,100 | 4,150 | 4,080 | 4,085 | -0.12% | 131,200 | 1803億1079万 | +4.9% |
| 12/23 | 4,050 | 4,095 | 4,045 | 4,090 | +1.36% | 105,600 | 1805億3149万 | +5.47% |
| 12/22 | （IR情報）15:30 遺伝性血管性浮腫（HAE）急性発作治療用血漿カリクレイン阻害薬「エクテリー錠300mg」の国内製造販売承認取得について |
| 12/22 | 4,045 | 4,055 | 4,010 | 4,035 | +0.37% | 145,200 | 1781億381万 | +4.51% |
| 12/19 | 4,050 | 4,060 | 4,015 | 4,020 | -1.47% | 145,100 | 1774億4171万 | +4.52% |
| 12/18 | 4,050 | 4,085 | 4,030 | 4,080 | +1.12% | 146,500 | 1800億9009万 | +6.53% |
| 12/17 | 4,035 | 4,055 | 3,995 | 4,035 | +0.37% | 169,400 | 1781億381万 | +5.82% |
| 12/16 | 4,010 | 4,055 | 3,995 | 4,020 | +0.25% | 218,100 | 1774億4171万 | +5.96% |
| 12/15 | 3,955 | 4,020 | 3,950 | 4,010 | +1.78% | 195,700 | 1770億31万 | +6.08% |
| 12/12 | 3,950 | 3,955 | 3,910 | 3,940 | +0.77% | 129,900 | 1739億1053万 | +4.59% |
| 12/11 | 4,010 | 4,010 | 3,900 | 3,910 | -1.51% | 162,400 | 1725億8634万 | +4.1% |
| 12/10 | 3,865 | 3,970 | 3,860 | 3,970 | +2.72% | 255,900 | 1752億3472万 | +5.98% |
| 12/09 | 3,830 | 3,865 | 3,805 | 3,865 | +0.26% | 153,500 | 1706億5万 | +3.48% |
| 12/08 | 3,785 | 3,855 | 3,785 | 3,855 | +2.53% | 190,100 | 1701億5865万 | +3.43% |
| 12/05 | 3,760 | 3,780 | 3,750 | 3,760 | -0.53% | 115,900 | 1659億6538万 | +1.1% |
| 12/04 | 3,770 | 3,780 | 3,755 | 3,780 | +0.13% | 128,100 | 1668億4817万 | +1.78% |
| 12/03 | 3,780 | 3,800 | 3,755 | 3,775 | -1.18% | 163,000 | 1666億2748万 | +1.75% |
| 12/02 | 3,815 | 3,830 | 3,790 | 3,820 | -0.26% | 125,000 | 1686億1376万 | +3.08% |
| 12/01 | 3,850 | 3,855 | 3,820 | 3,830 | -1.03% | 156,300 | 1690億5516万 | +3.51% |
| 11/28 | 3,830 | 3,875 | 3,820 | 3,870 | +1.57% | 209,500 | 1708億2075万 | +4.74% |
| 11/27 | 3,795 | 3,820 | 3,790 | 3,810 | -0.78% | 112,500 | 1681億7237万 | +3.28% |
| 11/26 | 3,800 | 3,840 | 3,790 | 3,840 | +1.19% | 113,000 | 1694億9656万 | +4.21% |
| 11/25 | 3,770 | 3,815 | 3,750 | 3,795 | +0.13% | 139,500 | 1675億1027万 | +3.13% |
| 11/21 | 3,695 | 3,790 | 3,695 | 3,790 | +2.57% | 168,900 | 1672億8957万 | +3.16% |
| 11/20 | 3,645 | 3,700 | 3,635 | 3,695 | +0.54% | 154,600 | 1630億9630万 | +0.68% |
| 11/19 | 3,670 | 3,685 | 3,665 | 3,675 | +0.14% | 97,300 | 1622億1350万 | +0.16% |
| 11/18 | 3,675 | 3,695 | 3,655 | 3,670 | -0.27% | 133,500 | 1619億9280万 | +0.05% |
| 11/17 | 3,665 | 3,695 | 3,655 | 3,680 | +0.55% | 183,700 | 1624億3420万 | +0.3% |
| 11/14 | 3,630 | 3,660 | 3,615 | 3,660 | +1.39% | 140,200 | 1615億5141万 | -0.33% |
| 11/13 | （IR情報）19:00 炎症性腸疾患治療薬「NM81」に関するライセンス及び共同開発契約締結について |
| 11/13 | 3,635 | 3,645 | 3,585 | 3,610 | -1.1% | 164,900 | 1593億4442万 | -1.72% |
| 11/12 | 3,580 | 3,680 | 3,570 | 3,650 | +1.96% | 239,300 | 1611億1001万 | -0.76% |
| 11/11 | 3,645 | 3,675 | 3,540 | 3,580 | -2.32% | 503,600 | 1580億2023万 | -2.72% |
| 11/10 | （IR情報）15:30 2026年3月期第2四半期(中間期)決算短信〔日本基準〕(連結) |
| 11/10 | （IR情報）15:30 「KP-001」の国内第III相検証的試験結果のお知らせ |
| 11/10 | 3,700 | 3,700 | 3,665 | 3,665 | -0.41% | 133,200 | 1617億7211万 | -0.54% |
| 11/07 | 3,660 | 3,695 | 3,645 | 3,680 | +0.27% | 126,500 | 1624億3420万 | -0.14% |
| 11/06 | 3,650 | 3,690 | 3,635 | 3,670 | +0.14% | 140,900 | 1619億9280万 | -0.35% |
| 11/05 | 3,695 | 3,725 | 3,655 | 3,665 | -0.68% | 160,800 | 1617億7211万 | -0.46% |
| 11/04 | 3,645 | 3,700 | 3,635 | 3,690 | +0.68% | 229,600 | 1628億7560万 | +0.19% |
| 10/31 | 3,670 | 3,690 | 3,635 | 3,665 | +0.25% | 125,300 | 1617億7211万 | -0.65% |
| 10/30 | 3,641 | 3,660 | 3,624 | 3,656 | +0.44% | 412,000 | 1613億7485万 | -1.08% |
| 10/29 | 3,669 | 3,678 | 3,626 | 3,640 | -0.79% | 183,500 | 1606億6861万 | -1.7% |
| 10/28 | 3,678 | 3,695 | 3,655 | 3,669 | -0.41% | 181,500 | 1619億4866万 | -1.13% |
| 10/27 | 3,680 | 3,690 | 3,666 | 3,684 | +0.44% | 130,900 | 1626億1076万 | -0.94% |
| 10/24 | 3,691 | 3,700 | 3,668 | 3,668 | -0.86% | 133,200 | 1619億452万 | -1.53% |
| 10/23 | 3,711 | 3,713 | 3,689 | 3,700 | -0.22% | 90,700 | 1633億1700万 | -0.88% |
| 10/22 | 3,716 | 3,732 | 3,701 | 3,708 | -0.22% | 102,700 | 1636億7011万 | -0.86% |
| 10/21 | 3,700 | 3,718 | 3,698 | 3,716 | +0.11% | 104,100 | 1640億2323万 | -0.85% |
| 10/20 | 3,702 | 3,716 | 3,674 | 3,712 | +1.31% | 111,500 | 1638億4667万 | -1.15% |
| 10/17 | 3,697 | 3,697 | 3,662 | 3,664 | -0.57% | 108,500 | 1617億2797万 | -2.6% |
| 10/16 | 3,670 | 3,689 | 3,657 | 3,685 | +0.46% | 74,600 | 1626億5490万 | -2.31% |
| 10/15 | 3,659 | 3,673 | 3,653 | 3,668 | +0.77% | 121,000 | 1619億452万 | -3.01% |
| 10/14 | （自社株買い）取締役会(2025年2月26日)での決議状況(取得期間2025年2月27日～2025年9月30日) |
| 10/14 | 3,644 | 3,663 | 3,611 | 3,640 | -1.65% | 225,500 | 1606億6861万 | -4.03% |
| 10/10 | 3,720 | 3,750 | 3,698 | 3,701 | -1.17% | 230,200 | 1633億6114万 | -2.71% |
| 10/09 | 3,700 | 3,745 | 3,700 | 3,745 | +1.13% | 157,500 | 1653億328万 | -1.73% |
| 10/08 | 3,732 | 3,757 | 3,701 | 3,703 | -0.59% | 153,700 | 1634億4942万 | -2.94% |
| 10/07 | 3,717 | 3,733 | 3,710 | 3,725 | +0.57% | 122,700 | 1644億2049万 | -2.46% |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
